SI1599461T1 - Tiolaktoni kot inhibitorji NAALADaze - Google Patents

Tiolaktoni kot inhibitorji NAALADaze

Info

Publication number
SI1599461T1
SI1599461T1 SI200431195T SI200431195T SI1599461T1 SI 1599461 T1 SI1599461 T1 SI 1599461T1 SI 200431195 T SI200431195 T SI 200431195T SI 200431195 T SI200431195 T SI 200431195T SI 1599461 T1 SI1599461 T1 SI 1599461T1
Authority
SI
Slovenia
Prior art keywords
compounds
activity
thiolactones
naaladase
disease
Prior art date
Application number
SI200431195T
Other languages
English (en)
Inventor
Takashi Tsukamoto
Barbara S Slusher
Original Assignee
Eisai Corp Of North Amarica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Corp Of North Amarica filed Critical Eisai Corp Of North Amarica
Publication of SI1599461T1 publication Critical patent/SI1599461T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
SI200431195T 2003-03-03 2004-03-03 Tiolaktoni kot inhibitorji NAALADaze SI1599461T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45064803P 2003-03-03 2003-03-03
EP04716834A EP1599461B1 (en) 2003-03-03 2004-03-03 THIOLACTONES AS NAALADase INHIBITORS
PCT/US2004/006178 WO2004078742A1 (en) 2003-03-03 2004-03-03 Thiolactones

Publications (1)

Publication Number Publication Date
SI1599461T1 true SI1599461T1 (sl) 2009-10-31

Family

ID=32962505

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431195T SI1599461T1 (sl) 2003-03-03 2004-03-03 Tiolaktoni kot inhibitorji NAALADaze

Country Status (15)

Country Link
US (4) US7125907B2 (sl)
EP (2) EP1599461B1 (sl)
JP (1) JP4773951B2 (sl)
AT (1) ATE433445T1 (sl)
AU (1) AU2004217969B2 (sl)
CA (1) CA2518234C (sl)
CY (1) CY1109356T1 (sl)
DE (1) DE602004021476D1 (sl)
DK (1) DK1599461T3 (sl)
ES (1) ES2326083T3 (sl)
MX (1) MXPA05009492A (sl)
PL (1) PL1599461T3 (sl)
PT (1) PT1599461E (sl)
SI (1) SI1599461T1 (sl)
WO (1) WO2004078742A1 (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE433445T1 (de) 2003-03-03 2009-06-15 Eisai Corp North America Thiolactone als naaladase inhibitoren
EP2111252A4 (en) * 2007-01-31 2010-12-01 Adam Heller MANAGEMENT OF PAIN BY ELECTROCHEMICAL PATHWAY
US20180236109A1 (en) 2015-08-20 2018-08-23 Universitat Zu Koln Pain Tracking by PET-imaging (Pain-TraP)
WO2021155167A1 (en) * 2020-01-31 2021-08-05 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239636A (en) * 1978-10-23 1980-12-16 Exxon Research & Engineering Co. Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions
JPH0532659A (ja) * 1991-08-01 1993-02-09 Tsumura & Co 糖尿病治療剤
GB9218810D0 (en) 1992-09-04 1992-10-21 Univ Birmingham Antiviral pyrimidine nucleosides
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
GB9602721D0 (en) 1996-02-09 1996-04-10 Pharmacia Spa Biologically active ureido derivatives useful in the treatment of multiple sclerosis
US5795877A (en) * 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5804602A (en) * 1996-06-17 1998-09-08 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
IL127605A0 (en) 1996-06-17 1999-10-28 Guilford Pharm Inc Methods of cancer treatment using naaladase inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5902817A (en) * 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6025345A (en) * 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6025344A (en) * 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6054444A (en) * 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5977090A (en) 1996-09-27 1999-11-02 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
GB9615202D0 (en) 1996-07-19 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
TR199901173T2 (xx) * 1996-09-27 1999-07-21 Guilford Pharmaceuticals, Inc. Canl�larda glutamat anormalli�inin tedavisi ve n�ronal aktivitenin d�zenlenmesi i�in y�ntemler ve NAALADase bile�imleri.
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en) * 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
US6395718B1 (en) * 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
ATE305449T1 (de) * 1998-07-06 2005-10-15 Guilford Pharm Inc Naaladase-hemmer anwendbar als pharmazeutische verbindungen und zusammensetzungen
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
JP5095050B2 (ja) * 1999-04-28 2012-12-12 ジョージタウン ユニバーシティー 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤
US6228888B1 (en) * 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
US6313159B1 (en) * 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US6348464B1 (en) * 1999-11-12 2002-02-19 Guilford Pharmaceuticals, Inc. Pyrrolecarbonylimino derivatives as naaladase inhibitors
WO2001091738A2 (en) 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating amyotrophic lateral sclerosis
WO2001092273A2 (en) * 2000-05-30 2001-12-06 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives
EP1292601A2 (en) * 2000-05-30 2003-03-19 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating retinal disorders and glaucoma
ATE363839T1 (de) * 2001-01-08 2007-06-15 Pathway Intermediates Ltd Autoinducer-verbindungen und ihre verwendung
FR2819253B1 (fr) * 2001-01-11 2004-12-03 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4234430B2 (ja) 2001-01-17 2009-03-04 エムジーアイ ジーピー インコーポレイティッド チオールを含むｎａａｌａｄアーゼ抑制物質
JP4625236B2 (ja) * 2001-05-11 2011-02-02 エーザイ インコーポレーテッド ＮＡＡＬＡＤａｓｅ阻害剤としてのヒドロキサム酸およびアシルヒドロキサミン
ATE419232T1 (de) * 2001-05-30 2009-01-15 Guilford Pharm Inc Thiolalkylbezoesäurederivate
AU2002364743A1 (en) 2001-12-28 2003-07-24 Guildford Pharmaceuticals Inc. Naaladase inhibitors for treating huntington's disease
WO2004078180A2 (en) * 2003-03-03 2004-09-16 Guilford Pharmaceuticals Inc. Naaladase inhibitors for treating opioid tolerance
ATE433445T1 (de) 2003-03-03 2009-06-15 Eisai Corp North America Thiolactone als naaladase inhibitoren

Also Published As

Publication number Publication date
US20070037798A1 (en) 2007-02-15
ATE433445T1 (de) 2009-06-15
US20100048667A1 (en) 2010-02-25
EP1599461B1 (en) 2009-06-10
US20080004334A1 (en) 2008-01-03
US7553866B2 (en) 2009-06-30
JP4773951B2 (ja) 2011-09-14
CA2518234C (en) 2012-11-13
EP1599461A1 (en) 2005-11-30
WO2004078742A1 (en) 2004-09-16
CA2518234A1 (en) 2004-09-16
MXPA05009492A (es) 2005-12-14
US7968593B2 (en) 2011-06-28
US7125907B2 (en) 2006-10-24
AU2004217969A1 (en) 2004-09-16
EP1988088A1 (en) 2008-11-05
PL1599461T3 (pl) 2009-10-30
CY1109356T1 (el) 2014-07-02
US20050004203A1 (en) 2005-01-06
JP2006519858A (ja) 2006-08-31
AU2004217969B2 (en) 2011-03-03
DE602004021476D1 (de) 2009-07-23
PT1599461E (pt) 2009-07-20
ES2326083T3 (es) 2009-09-30
DK1599461T3 (da) 2009-08-17

Similar Documents

Publication Publication Date Title
WO2003057670A3 (en) Indoles as naaladase inhibitors
WO2002057222A3 (en) Thiol-based naaladase inhibitors
WO2001092273A3 (en) Benzenedicarboxylic acid derivatives
WO2005025511A3 (en) Potassium channel mediated delivery of agents through the blood-brain barrier
CY1108893T1 (el) Παραγωγα θειοαλκυλ βενζοϊκου οξεος
BRPI0407910A (pt) usos de compostos para prevenção, tratamento ou diagnóstico, em um indivìduo, de um distúrbio de agregação de proteìna
BR0313299A (pt) Processos para tratar distúrbios mediados por anidrase carbÈnica
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
DE69940951D1 (de) Nd wachstumshemmende mittel
WO2003065006A3 (en) Methods and compositions for treating cancer
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
IL140499A0 (en) Nalladase inhibitors useful as pharmaceutical compounds and compositions
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
CY1109356T1 (el) Θειολακτονες ως αναστολεις της νααladασης
WO2002062777A3 (en) Amino ceramide-like compounds and therapeutic methods of use
MXPA03010328A (es) Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
WO2004030618A3 (en) Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
WO2003065871A3 (en) Methods and compositions for treating hematological disorders
WO2005000406A3 (en) Treatment of amyloid- and epileptogenesis-associated diseases
WO2002089848A3 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
WO2002086084A3 (en) Sequence characteristics of bladder cancer
BR0308911A (pt) Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
WO2004080535A3 (en) Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777